Background
Infectious complications are a significant cause of morbidity and mortality in patients undergoing allogeneic haematopoietic stem cell transplantation (Allo-SCT). The BATMO ...(Best-Antimicrobial-Therapy-TMO) is an innovative program for infection prevention and management and has been used in our centre since 2019. The specific features of the BATMO protocol regard both prophylaxis during neutropenia (abandonment of fluoroquinolone, posaconazole use in high-risk patients, aerosolized liposomal amphotericin B use until engraftment or a need for antifungal treatment, and letermovir use in CMV-positive recipients from day 0 to day +100) and therapy (empirical antibiotics based on patient clinical history and colonization, new antibiotics used in second-line according to antibiogram with the exception of carbapenemase-producing
K pneumoniae
for which the use in first-line therapy is chosen).
Methods
Data on the infectious complications of 116 transplant patients before BATMO protocol (Cohort A; 2016 - 2018) were compared to those of 84 transplant patients following the introduction of the BATMO protocol (Cohort B; 2019 - 2021). The clinical and transplant characteristics of the 2 Cohorts were comparable, even though patients in Cohort B were at a higher risk of developing bacterial, fungal, and CMV infections, due to a significantly higher proportion of myeloablative regimens and haploidentical donors.
Results
No change in the incidence of infections with organ localization was observed between the two Cohorts. A significant reduction in
Clostridioides difficile
infections by day +100 was observed in Cohort B (47% vs. 15%; p=0.04). At day +30, a higher incidence of Gram-negative bloodstream infections (BSIs) was observed in Cohort B (12% vs. 23%; p=0.05). By day +100 and between days +100 and +180, the incidence of BSIs and of the various etiological agents, the mortality from Gram-negative bacteria, and the incidence of invasive fungal infections were not different in the two Cohorts. The incidence of CMV reactivations by day +100 dropped drastically in patients of Cohort B, following letermovir registration (51% vs. 15%; p=0.00001).
Discussion
The results of this study suggest that the BATMO program is safe. In particular, the choice to avoid prophylaxis with fluoroquinolone was associated with an increase in Gram-negative BSIs by day +30, but this did not translate into higher levels of mortality. Moreover, this strategy was associated with a significant reduction of
Clostridiodes difficile
infections. The efficacy of anti-CMV prophylaxis with letermovir was confirmed by a significant reduction in CMV reactivations. Even though patients in Cohort B were at higher risk of developing fungal infections (more haploidentical transplants with more myeloablative regimens), the extensive use of posaconazole for prophylaxis balanced this risk, and no increase in the incidence of fungal-associated complications was observed.
spp. endocarditis is a severe and hard-to-treat infection. Immunosuppressed subjects and carriers of prosthetic valves or intracardiac devices are at risk. This article presents the case of an ...immunocompetent 74-year-old man affected by endocarditis of the prosthetic aortic valve. After Bentall surgery, cultures of the removed valve demonstrated
as the etiological agent. The patient was treated with amphotericin B at first and subsequently with fluconazole. Given the fragility of the patient and the aggressiveness of the pathogen, life-long prophylactic therapy with fluconazole was prescribed. After 5 years follow-up, no drug-related toxicities were reported and the patient never showed any signs of recurrence. The review of the literature illustrates that
spp. endocarditis may present even many years after heart surgery, and it is often associated with massive valve vegetations, severe embolic complications, and unfavorable outcome. Due to the absence of international guidelines, there is no unanimous therapeutic approach, but amphotericin B and azoles are usually prescribed. Additionally, a prompt surgical intervention seems to be of paramount importance. When dealing with a life-threatening disease, such as mycotic endocarditis of prosthetic valves, it is essential to consider and treat even rare etiological agents such as
spp.
Central nervous system infections are among the most severe infectious conditions in the neonatal period and are still burdened by significant mortality, especially in preterm infants and those with ...a low birth weight or other comorbidities. In this study, we examined the role of fosfomycin-containing antibiotic regimens in neonates with central nervous system infections. We included six neonates over a period of five years: four with meningitis and two with cerebral abscesses. All patients underwent fosfomycin therapy after failing first-line antibiotic regimens. Of the six neonates, two died; two developed neurological and psychomotor deficits and two recovered uneventfully. None of the neonates experienced adverse reactions to fosfomycin, confirming the safety of the molecule in this population. In conclusion, the deep penetration in the central nervous system, the unique mechanism of action, the synergy with other antibiotic therapies, and the excellent safety profile all make fosfomycin an attractive drug for the treatment of neonatal central nervous system infections.
Cefiderocol is a new molecule effective against multidrug-resistant (MDR) Gram-negative pathogens. Currently, there is limited evidence regarding the use of cefiderocol in central nervous system ...(CNS) infections. Data on the cerebrospinal fluid penetration rate of cefiderocol are limited and heterogeneous, and there is no consensus on the dosing scheme of cefiderocol to penetrate the blood-brain barrier. We present a case series and a literature review of CNS infections caused by MDR pathogens that were treated with cefiderocol: some of these patients were treated with different dose schemes of cefiderocol and underwent therapeutic drug monitoring both on plasma and cerebrospinal fluid (CSF). The CSF penetration rates and the clinical outcomes were evaluated.
To describe the epidemiology of superinfections (occurring > 48 hr after hospital admission) and their impact on the ICU and 28-day mortality in patients with coronavirus disease 2019 with acute ...respiratory distress syndrome, requiring mechanical ventilation.
Retrospective analysis of prospectively collected observational data.
University-affiliated adult ICU.
Ninety-two coronavirus disease 2019 patients admitted to the ICU from February 21, 2020, to May 6, 2020.
None.
The prevalence of superinfection at ICU admission was 21.7%, and 53 patients (57.6%) had at least one superinfection during ICU stay, with a total of 75 (82%) ventilator-associated pneumonia and 57 (62%) systemic infections. The most common pathogens responsible for ventilator-associated pneumonia were
(
= 26, 34.7%) and
(
= 14, 18.7%). Bloodstream infection occurred in 16 cases, including methicillin-resistant
(
= 8, 14.0%),
species (
= 6, 10.5%), and
species (
= 2, 3.5%). Fungal infections occurred in 41 cases, including 36 probable (30 by
, six by
) and five proven invasive candidiasis (three
, two
). Presence of bacterial infections (odds ratio, 10.53; 95% CI, 2.31-63.42;
= 0.005), age (odds ratio, 1.17; 95% CI, 1.07-1.31;
= 0.001), and the highest Sequential Organ Failure Assessment score (odds ratio, 1.27; 95% CI, 1.06-1.63;
= 0.032) were independently associated with ICU or 28-day mortality.
Prevalence of superinfections in coronavirus disease 2019 patients requiring mechanical ventilation was high in this series, and bacterial superinfections were independently associated with ICU or 28-day mortality (whichever comes first).
A hyperinflammatory syndrome (HIS) may cause a life-threatening acute respiratory distress syndrome (ARDS) in patients with COVID-19 pneumonia.
A prospective series of 100 consecutive patients ...admitted to the Spedali Civili University Hospital in Brescia (Italy) between March 9th and March 20th with confirmed COVID-19 pneumonia and ARDS requiring ventilatory support was analyzed to determine whether intravenous administration of tocilizumab (TCZ), a monoclonal antibody that targets the interleukin 6 (IL-6) receptor, was associated with improved outcome. Tocilizumab was administered at a dosage of 8 mg/kg by two consecutive intravenous infusions 12 h apart. A third infusion was optional based on clinical response.
The outcome measure was an improvement in acute respiratory failure assessed by means of the Brescia COVID Respiratory Severity Score (BCRSS 0 to 8, with higher scores indicating higher severity) at 24–72 h and 10 days after tocilizumab administration.
Out of 100 treated patients (88 M, 12 F; median age: 62 years), 43 received TCZ in the intensive care unit (ICU), while 57 in the general ward as no ICU beds were available. Of these 57 patients, 37 (65%) improved and suspended noninvasive ventilation (NIV) (median BCRSS: 1 IQR 0–2), 7 (12%) patients remained stable in NIV, and 13 (23%) patients worsened (10 died, 3 were admitted to ICU). Of the 43 patients treated in the ICU, 32 (74%) improved (17 of them were taken off the ventilator and were discharged to the ward), 1 (2%) remained stable (BCRSS: 5) and 10 (24%) died (all of them had BCRSS≥7 before TCZ). Overall at 10 days, the respiratory condition was improved or stabilized in 77 (77%) patients, of whom 61 showed a significant clearing of diffuse bilateral opacities on chest x-ray and 15 were discharged from the hospital. Respiratory condition worsened in 23 (23%) patients, of whom 20 (20%) died.
All the patients presented with lymphopenia and high levels of C-reactive protein (CRP), fibrinogen, ferritin and IL-6 indicating a HIS. During the 10-day follow-up, three cases of severe adverse events were recorded: two patients developed septic shock and died, one had gastrointestinal perforation requiring urgent surgery and was alive at day 10.
In conclusion, our series showed that COVID-19 pneumonia with ARDS was characterized by HIS. The response to TCZ was rapid, sustained, and associated with significant clinical improvement.
First isolated in the 1960s methicillin-resistant Staphylococcus aureus (MRSA) has become a leading hospital acquired (HA) pathogen, although community acquired isolates (CA-MRSA) are on the rise, ...particularly in the USA. Treatment of serious MRSA infections has been based for many years upon the use of glycopeptides, i.e. vancomycin and teicoplanin. Other drugs indicated in particular clinical settings, such as prosthetic valve endocarditis or osteomyelitis, are rifampin, gentamycin, fusidic acid, minocycline, co-trimoxazole, clindamycin. Quinolones and doxycycline may be active on some MRSA isolates, and add some this important clinical setting. In the last few years new anti-MRSA drugs have been registered and patented, expanding therapeutic opportunities, i.e. linezolid, the first oxazolidinone, available both as oral and parenteral formulation in being the most widely used new anti-MRSA agent, quinupristin-dalfopristin, daptomycin, a novel lipopeptide, active on germs both in the replicating and in the resting phase, and tigecycline, the first approved glycylcycline. Other drugs from different classes are in the pipeline and will further enhance in the next few years our therapeutic armamentarium: three glycopeptides, i.e. dalbavancin, telavancin, and oritavancin, two broad spectrum cephalosporins, ceftobiprole and ceftaroline, iclaprim, a diaminopyrimidine, as well as a carbapenem, CS-023/RO-4908463, and adjuvant therapies such as the monoclonal antibody tefibazumab.
In an Italian long-term-care facility (LTCF), we observed a 17.5% adherence to hand hygiene (HH), as well as 47.5% rate of glove use. Performing a procedure at high risk for cross-transmission of ...germs was the factor most strongly associated with noncompliance (odds ratio = 13.3; 95% confidence interval = 6.2 to 28.8; P < .0001). No significant differences in compliance related to health care worker category were found. Adherence to HH in the LTCF was similar to that found in a rehabilitation medicine unit of an acute care hospital (15.8%) but significantly lower than that reported in an infectious disease unit (53.7%; P < .0001). Our findings indicate that compliance with HH is a similar problem in LTCFs as in acute care facilities.
In an Italian hospital, we observed that hand hygiene was performed in 638 (19.6%) of 3,253 opportunities, whereas gloves were worn in 538 (44.2%) 1,218 of opportunities. We observed an inverse ...correlation between the intensity of care and the rate of hand hygiene compliance (
\documentclass{aastex}
\usepackage{amsbsy}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{bm}
\usepackage{mathrsfs}
\usepackage{pifont}
\usepackage{stmaryrd}
\usepackage{textcomp}
\usepackage{portland,xspace}
\usepackage{amsmath,amsxtra}
\usepackageOT2,OT1{fontenc}
\newcommand\cyr{
\renewcommand\rmdefault{wncyr}
\renewcommand\sfdefault{wncyss}
\renewcommand\encodingdefault{OT2}
\normalfont
\selectfont}
\DeclareTextFontCommand{\textcyr}{\cyr}
\pagestyle{empty}
\DeclareMathSizes{10}{9}{7}{6}
\begin{document}
\landscape
$\mathrm{R}\,^{2}=0.057$
\end{document}
;
\documentclass{aastex}
\usepackage{amsbsy}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{bm}
\usepackage{mathrsfs}
\usepackage{pifont}
\usepackage{stmaryrd}
\usepackage{textcomp}
\usepackage{portland,xspace}
\usepackage{amsmath,amsxtra}
\usepackageOT2,OT1{fontenc}
\newcommand\cyr{
\renewcommand\rmdefault{wncyr}
\renewcommand\sfdefault{wncyss}
\renewcommand\encodingdefault{OT2}
\normalfont
\selectfont}
\DeclareTextFontCommand{\textcyr}{\cyr}
\pagestyle{empty}
\DeclareMathSizes{10}{9}{7}{6}
\begin{document}
\landscape
$P< .001$
\end{document}
), but no such association was observed for the rate of glove use compliance (
\documentclass{aastex}
\usepackage{amsbsy}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{bm}
\usepackage{mathrsfs}
\usepackage{pifont}
\usepackage{stmaryrd}
\usepackage{textcomp}
\usepackage{portland,xspace}
\usepackage{amsmath,amsxtra}
\usepackageOT2,OT1{fontenc}
\newcommand\cyr{
\renewcommand\rmdefault{wncyr}
\renewcommand\sfdefault{wncyss}
\renewcommand\encodingdefault{OT2}
\normalfont
\selectfont}
\DeclareTextFontCommand{\textcyr}{\cyr}
\pagestyle{empty}
\DeclareMathSizes{10}{9}{7}{6}
\begin{document}
\landscape
$\mathrm{R}\,^{2}=0.014$
\end{document}
;
\documentclass{aastex}
\usepackage{amsbsy}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{bm}
\usepackage{mathrsfs}
\usepackage{pifont}
\usepackage{stmaryrd}
\usepackage{textcomp}
\usepackage{portland,xspace}
\usepackage{amsmath,amsxtra}
\usepackageOT2,OT1{fontenc}
\newcommand\cyr{
\renewcommand\rmdefault{wncyr}
\renewcommand\sfdefault{wncyss}
\renewcommand\encodingdefault{OT2}
\normalfont
\selectfont}
\DeclareTextFontCommand{\textcyr}{\cyr}
\pagestyle{empty}
\DeclareMathSizes{10}{9}{7}{6}
\begin{document}
\landscape
$P=.078$
\end{document}
). Rates of compliance with hand hygiene and glove use recommendations follow different behavioral patterns.
PDF
